NK/LAK细胞对人口腔癌耐细胞药株杀伤活性的观察

摘要/Abstract

摘要： 目的明确免疫活性细胞对肿瘤细胞的杀伤活性是否与肿瘤的耐药性相关。方法采用连续形态学观察及MTT比色法,研究淋巴因子激活的杀伤(LAK)细胞及自然杀伤(NK)细胞,对人口腔癌耐药细胞株KBV200耐药性逆转前后及亲本敏感株KB的杀伤活性。(1)在肿瘤细胞与LAK细胞共育后3 h内连续在倒置显微镜下观察LAK细胞对上述3者的杀瘤效应;(2)采用MTT比色法检测NK及LAK对3株细胞的杀伤率。结果与KB细胞组相比,在KBV200和KBV200+维拉帕米组,LAK细胞出现在靶细胞周围的时间早、数量多,伸出伪足的LAK细胞比率高,出现集落样细胞团块时间亦早。NK、LAK细胞对KBV200细胞株耐药性逆转前后的杀伤率均明显高于敏感株KB(P<0.05),而对耐药株耐药性逆转前后的杀伤率无统计学差异(P>0.05);LAK对各株的杀伤活力均明显强于NK细胞(P<0.05)。结论免疫活性细胞对KBV200细胞株有较强的杀伤作用,逆转耐药性不降低免疫活性细胞杀伤活力,提示细胞过继免疫治疗可能成为控制化疗耐药病人病情发展的一个有效手段。

Abstract: Objective To understand the relation between cytotoxic activity of immunologic effector cells and multidrug resis-tance of the tumor cells. Methods Continuous observation of the morphological changes and MTT colorimetry were em-ployed to evaluate the cytotoxic activity of lymphokine-activated killer (LAK) cells and natural killer (NK) cells against mul-tidrug-resistant (MDR) human oral carcinoma cell line-KBV200 (before and after reversal of MDR) and parental drug-sensi-tive cell line KB. The morphologic changes of LAK cells and the 3 target cell lines were observed continuously under inverted microscope 3 h after co-culture of LAK cells with one of three target cell lines respectively. The lysis rates of three tumor cell lines in response to co-culture with LAK or NK cells were determined using MTT colorimetry. Results In comparison with the parental drug-sensitive cell line KB, both KBV200 and its reserved cell line by verapamil (KBVV) showed earlier adher-ence and greater number of cells lysed by LAK. In MTT colorimetry assay, the cytotoxicity of both LAK and NK cells against the 3 cell lines was associated with the effector-to-target (E/T) cell ratio; the lysis rates of KBV200 and reversed KBV200 cells by verapamil in response to LAK and NK cells were higher than that of KB cells (P<0.05), but KBV200 and KBVV did not significantly differ (P>0.05). At the same E/T ratio, LAK cells possessed stronger cytotoxicity than NK cells against all the tumor cell lines (P<0.05). Conclusions Immunologic effector cells possess strong cytotoxic activity against mutidrug-resistant cell line KBV200. Modulation of MDR does not decrease the cytotoxic activity of the immunologic effector cells. The results of this study suggest that adoptive cell immunotherapy with immunologic effector cells may be of value in controlling the progress of MDR tumors.

中图分类号:

R392.12

郑颖娟, 张健, 汪森明, 张积仁. NK/LAK细胞对人口腔癌耐细胞药株杀伤活性的观察[J]. 南方医科大学学报, 2004, 24(04): 392-396.

ZHENG Ying-juan, ZHANG Jian, WANG Sen-ming, ZHANG Ji-ren. Morpholoical observation on NK/LAK cell-mediated lysis of human oral carcimoma cells[J]. Journal of Southern Medical University, 2004, 24(04): 392-396.

参考文献

[1] 张晓红,张福荣,籍秀娟,等.KB细胞耐药株的建立及其耐药机制的探讨[J].药学学报,1994,29(4):246-51.Zhang XH, Zhang FR, Ji XJ, et al. Generation of multiple drug-resistant human KB carcinoma cell line and investigation on mechanism of multiple drag-resistance of KBV200[J]. Acta Pharm Sin,1994, 29(4): 246-51.
[2] 沈关心,周汝麟.现代免疫学实验技术[M].武汉:湖北科学技术出版社,1998.308.
[3] Lotze MT, Grimm EA, Mazumder A, et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor[J]. Cancer Res, 1981, 41: 4420-5.
[4] Hoffman DM, Gitlitz BJ, Belldegrun A, et al. Adoptive cellular therapy[J]. Semin Oncol, 2000, 27(2): 221-33.
[5] Classen CF, Fulda S, Friesen C, et al. Decreased sensitivity of dragresistant cells towards T cell cytotoxicity[J]. Leukemia, 1999, 13(3): 410-8.
[6] Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells[J]. Cell Immunol, 1996, 169(1): 85-90.
[7] Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenhon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes[J]. J Exp Med, 1982, 155: 1832-41.
[8] 张健,张积仁,汪森明,等.CD3AK、LAK对KB、KBV200细胞株耐药逆转前后的杀伤作用[J].中华微生物学和免疫学杂志,2001,21(3):288-91.Zhang J, Zhang JR, Wang SM, et al. CD3AK and LAK’s susceptibility and multidrug resistance in KB and KBV200 cell line[J]. Chin J Microbiol Immunol, 2001, 21(3): 288-91.
[9] Rivoltini L, Colombo MP, Supino R, et al. Modulation ofmultidrug resistance by verapamil or mdrl anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line[J]. Int J Cancer, 1990, 46(4): 727-32.
[10] Robin S, Treichel RS, Olken S. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in hman leukemic cell lines[J]. Int J Cancer,1992, 50(2): 305-10.
[11] Correale P, Tagliaferri P, Guarrasi R, et al. Extracellular adenosine 5’ triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation[J]. Immunol Lett, 1997, 55(2): 69-78.
[12] 马强,张振书,张亚力,等.人结肠癌LoVo/Adr细胞耐药性与细胞内浓度的关系[J].癌症,2002,21(8):846-9.Ma Q, Zhang ZS, Zhang YL, et al. Relationship between multidmg resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration[J]. Chin J Cancer, 2002, 21 (8):846-9.
[13] 张健,张积仁,袁亚维,等.KBV200细胞株耐药逆转前后HLA、B7抗原的表达[J].第一军医大学学报,2000,20(6):481-4.Zhang J, Zhang JR, Yunn YW, et al. Expressions of HLA and B7 in KBv200 cell line before and after reversion resistance[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2000, 20(6): 481-4.
[14] 袁亚维,孙爱民,李传刚,等.KBV200细胞多药耐药与蛋白激酶α亚型表达的关系[J].第一军医大学学报,2002,22(3):215-9.Yuan YW, Sun AM, Li CG, et al. Correlation of protein kinase C isoform expression with multidrug resistance in KBv200 cells[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22 (3):215-9.
[15] Rivolitini L, C attoretti G, Arienti F, et al. The high lysability by LAK cells of colon-carcinoma cells resistant to doxombicin is associated with a high expression of ICAM-1, LFA-3, NCA and a lessdifferentiated phentype[J]. Int J Cancer, 1991, 47(4): 746-54.
[16] 陈俊,袁亚维,张积仁等.耐药乳腺癌MCF-Adr细胞c-myc的表达上调及耐药关系[J].第一军医大学学报,2002,22(2):124-6.Chen J, Yuan YW, Zhang JR, et al. Up-regulation of c-myc expression in MCF-Adr human breast cancer cells and its association with resistance against doxorubicin[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22(2): 124-6.
[17] Rivolitini L, Gambacorti-passerini C, Supino R, et al. Generation and partial charaterization of melanoma sublines resistant to lymphokine-activated killer (LAK) cells. Relevance to doxorubicin resistance[J]. Int J Cancer, 1989, 43(4): 880-5.